Manipulation of the anabolic and catabolic responses with BMP-2 and zoledronic acid in a rat femoral fracture model

Bone

Volumn 49, Issue 4, 2011, Pages 777-782

  Doi, Yuji ^a   Miyazaki, Masashi ^a   Yoshiiwa, Toyomi ^a   Hara, Katsutoshi ^a   Kataoka, Masashi ^a   Tsumura, Hiroshi ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Anabolism; Bisphosphonate; Bone morphogenetic protein; Catabolism; Fracture healing

Indexed keywords

RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BIOSYNTHESIS; BONE METABOLISM; BONE RADIOGRAPHY; BONE STRUCTURE; CALLUS; CATABOLISM; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENERGY ABSORPTION; FEMUR FRACTURE; FRACTURE HEALING; HISTOPATHOLOGY; IMAGE ANALYSIS; MALE; MICRO-COMPUTED TOMOGRAPHY; MONOTHERAPY; NONHUMAN; RAT; RIGIDITY; SCORING SYSTEM; SINGLE DRUG DOSE; SYSTEMIC THERAPY; TRABECULAR BONE; WEIGHT BEARING;

ANABOLIC AGENTS; ANIMALS; BIOMECHANICS; BONE MORPHOGENETIC PROTEIN 2; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMORAL FRACTURES; HUMANS; IMIDAZOLES; MALE; PALPATION; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; TRANSFORMING GROWTH FACTOR BETA; X-RAY MICROTOMOGRAPHY;

EID: 80052299713     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.07.005     Document Type: Article

References (29)

1. Little D.G., Ramachandran M., Schindeler A. The anabolic and catabolic responses in bone repair. J Bone Joint Surg Br 2007, 89:425-433.
2. Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Yano K., et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998, 253:395-400.
3. Xu D., Wang S., Liu W., Liu J., Feng X. A novel receptor activator of NF-kappaB (RANK) cytoplasmic motif plays an essential role in osteoclastogenesis by committing macrophages to the osteoclast lineage. J Biol Chem 2006, 281:4678-4690.
4. Welch R.D., Jones A.L., Bucholz R.W., Reinert C.M., Tjia J.S., Pierce W.A., et al. Effect of recombinant human bone morphogenetic protein-2 on fracture healing in a goat tibial fracture model. J Bone Miner Res 1998, 13:1483-1490.
5. Jones A.L., Bucholz R.W., Bosse M.J., Mirza S.K., Lyon T.R., Webb L.X., et al. Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects. A randomized, controlled trial. J Bone Joint Surg Am 2006, 88:1431-1441.
6. Bouxsein M.L., Turek T.J., Blake C.A., D'Augusta D., Li X., Stevens M., et al. Recombinant human bone morphogenetic protein-2 accelerates healing in a rabbit ulnar osteotomy model. J Bone Joint Surg Am 2001, 83-A:1219-1230.
7. Garrison K.R., Shemilt I., Donell S., Ryder J.J., Mugford M., Harvey I., et al. Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst Rev Jun 2010, 16:CD006950.
8. Garrison K.R., Donell S., Ryder J., Shemilt I., Mugford M., Harvey I., et al. Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. Health Technol Assess 2007, 11:1-150. [iii-iv].
9. Kanatani M., Sugimoto T., Kaji H., Kobayashi T., Nishiyama K., Fukase M., et al. Stimulatory effect of bone morphogenetic protein-2 on osteoclast-like cell formation and bone-resorbing activity. J Bone Miner Res 1995, 10:1681-1690.
10. Okamoto M., Murai J., Yoshikawa H., Tsumaki N. Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development. J Bone Miner Res 2006, 21:1022-1033.
11. Louis-Ugbo J., Kim H.S., Boden S.D., Mayr M.T., Li R.C., Seeherman H., et al. Retention of 125I-labeled recombinant human bone morphogenetic protein-2 by biphasic calcium phosphate or a composite sponge in a rabbit posterolateral spine arthrodesis model. J Orthop Res 2002, 20:1050-1059.
12. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
13. Hosking D., Lyles K., Brown J.P., Fraser W.D., Miller P., Curiel M.D., et al. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res 2007, 22:142-148.
14. Ross J.R., Saunders Y., Edmonds P.M., Patel S., Broadley K.E., Johnston S.R. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003, 327:469.
15. Amanat N., McDonald M., Godfrey C., Bilston L., Little D. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res 2007, 22:867-876.
16. Schimmer R.C., Bauss F. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. Clin Ther 2003, 25:19-34.
17. Little D.G., McDonald M., Bransford R., Godfrey C.B., Amanat N. Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model. J Bone Miner Res 2005, 20:2044-2052.
18. Miyazaki M., Morishita Y., He W., Hu M., Sintuu C., Hymanson H.J., et al. A porcine collagen-derived matrix as a carrier for recombinant human bone morphogenetic protein-2 enhances spinal fusion in rats. Spine J 2009, 9:22-30.
19. Morishita Y., Naito M., Miyazaki M., He W., Wu G., Wei F., et al. Enhanced effects of BMP-binding peptide combined with recombinant human BMP-2 on the healing of a rodent segmental femoral defect. J Orthop Res 2010, 28:258-264.
20. Yamamoto M., Takahashi Y., Tabata Y. Controlled release by biodegradable hydrogels enhances the ectopic bone formation of bone morphogenetic protein. Biomaterials 2003, 24:4375-4383.
21. Turner C.H., Burr D.B. Basic biomechanical measurements of bone: a tutorial. Bone 1993, 14:595-608.
22. Binkley N., Krueger D., Engelke J., Crenshaw T., Suttie J. Vitamin K supplementation does not affect ovariectomy-induced bone loss in rats. Bone 2002, 30:897-900.
23. Patel V.V., Zhao L., Wong P., Pradhan B.B., Bae H.W., Kanim L., et al. An in vitro and in vivo analysis of fibrin glue use to control bone morphogenetic protein diffusion and bone morphogenetic protein-stimulated bone growth. Spine J 2006, 6:397-403.
24. Little D.G., Smith N.C., Williams P.R., Briody J.N., Bilston L.E., Smith E.J., et al. Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. J Bone Miner Res 2003, 18:1300-1307.
25. McDonald M.M., Dulai S., Godfrey C., Amanat N., Sztynda T., Little D.G. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling. Bone 2008, 43:653-662.
26. Matos M.A., Tannuri U., Guarniero R. The effect of zoledronate during bone healing. J Orthop Traumatol 2010, 11:7-12.
27. McClellan J.W., Mulconrey D.S., Forbes R.J., Fullmer N. Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). J Spinal Disord Tech 2006, 19:483-486.
28. Pradhan B.B., Bae H.W., Dawson E.G., Patel V.V., Delamarter R.B. Graft resorption with the use of bone morphogenetic protein: lessons from anterior lumbar interbody fusion using femoral ring allografts and recombinant human bone morphogenetic protein-2. Spine (Phila Pa 1976) 2006, 31:E277-E284.
29. Sheeherman H.J., Ki X., Blake C., Gavin D., Wozney J.M., Bouxsein M.L. Histology indicates bisphosphonate limits transient resorption without decreasing subsequent bone induction in non human primate core defects treated with BMP-2/ACS. J Bone Miner Res 2001, 16(S1):S438.